Ferric Carboxymaltose

Indications :

Contraindications:

Dosing :

MoA :

Pharmacokinetics :

Toxicities/Monitoring :

• Can result in transient hypophosphatemia.
  • Although most reported cases occur after a patient receives repeated doses, hypophosphatemia has occurred after a single dose.
  • The mechanism has shown to be secondary to increases in fibroblast growth factor 23 (FGF-23), which cause phosphaturia and a decrease in 1-hydroxylation of vitamin D.

References:

• MKSAP